These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7430335)

  • 61. No effect of cefaclor on theophylline pharmacokinetics.
    Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Hempenius J
    Eur J Respir Dis; 1985 Jan; 66(1):47-9. PubMed ID: 3979475
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of in vitro antibacterial activity of three oral cephalosporins: cefaclor, cephalexin, and cephradine.
    Silver MS; Counts GW; Zeleznik D; Turck M
    Antimicrob Agents Chemother; 1977 Nov; 12(5):591-6. PubMed ID: 921255
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Influence of cefaclor, phenethicillin, co-trimoxazole and doxycycline on colonization resistance in healthy volunteers.
    Vollaard EJ; Clasener HA; van Griethuysen AJ; Janssen AJ; Sanders-Reijmers AH; Muller NF; Huige PJ
    J Antimicrob Chemother; 1988 Nov; 22(5):747-58. PubMed ID: 3145269
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BMY 28100, a new oral cephalosporin.
    Leitner F; Pursiano TA; Buck RE; Tsai YH; Chisholm DR; Misiek M; Desiderio JV; Kessler RE
    Antimicrob Agents Chemother; 1987 Feb; 31(2):238-43. PubMed ID: 3105449
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Concentration of cefaclor in human prostatic tissue.
    Smith RP; Schmid GP; Baltch AL; Sutphen NT; Hammer MC
    Am J Med Sci; 1981; 281(1):19-24. PubMed ID: 7468636
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cefaclor--a new oral cephalosporin.
    Drug Ther Bull; 1979 Aug; 17(18):69-70. PubMed ID: 498945
    [No Abstract]   [Full Text] [Related]  

  • 67. In vitro susceptibility studies with cefaclor and cephalexin.
    Scheld WM; Korzeniowski OM; Sande MA
    Antimicrob Agents Chemother; 1977 Aug; 12(2):290-2. PubMed ID: 900924
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interpretation of pneumococcal susceptibility tests with cefaclor.
    Preston DA
    J Clin Microbiol; 1999 Jun; 37(6):2115. PubMed ID: 10383259
    [No Abstract]   [Full Text] [Related]  

  • 69. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.
    Kamimura T; Kojo H; Matsumoto Y; Mine Y; Goto S; Kuwahara S
    Antimicrob Agents Chemother; 1984 Jan; 25(1):98-104. PubMed ID: 6561017
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of the Autobac 1 susceptibility testing system in a clinical diagnostic laboratory.
    Mogyoros M; Morgan JR; Smith JA
    Antimicrob Agents Chemother; 1977 Apr; 11(4):750-2. PubMed ID: 856028
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cefaclor: clinical and bacteriological evaluation in 45 cases.
    Gómez-Lus R; Martinez-Piriz R; Espinosa C; Guillen G; Gómez-Agudo G; Clavel A
    Postgrad Med J; 1979; 55 Suppl 4():70-1. PubMed ID: 44909
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.
    Bill NJ; Washington JA
    Antimicrob Agents Chemother; 1977 Mar; 11(3):470-4. PubMed ID: 301005
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative efficacies of erythromycin-sulfisoxazole and cefaclor in acute otitis media: a double blind randomized trial.
    Bergeron MG; Ahronheim G; Richard JE; Riding K; Cron C; Bryer D; Macdonald N; Bouchard M; Young J; Dempsey EE
    Pediatr Infect Dis J; 1987 Jul; 6(7):654-60. PubMed ID: 3302918
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In vitro susceptibility of selected bacteria to cefaclor.
    Valenti AJ; Andriole VT
    Yale J Biol Med; 1977; 50(5):465-9. PubMed ID: 341537
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria.
    Shadomy S; Wagner G; Carver M
    Antimicrob Agents Chemother; 1977 Nov; 12(5):609-13. PubMed ID: 921258
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Single oral dose of cefaclor for the treatment of infections with penicillinase-producing strains of Neisseria gonorrhoeae.
    Tupasi TE; Calubiran OV; Torres CA
    Br J Vener Dis; 1982 Jun; 58(3):176-9. PubMed ID: 6805850
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem.
    Jones RN; Barry AL
    J Clin Microbiol; 1988 Apr; 26(4):770-3. PubMed ID: 3259247
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of cefaclor on the normal human oropharyngeal and intestinal microflora.
    Nord CE; Heimdahl A; Lundberg C; Marklund G
    Scand J Infect Dis; 1987; 19(6):681-5. PubMed ID: 3441750
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Serum and tissue concentrations after a single dose of cefaclor].
    Plaue R; Müller O; Fabricius K; Bethke RO
    Infection; 1979; 7(5):252-5. PubMed ID: 511343
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of the E test for antimicrobial susceptibility testing of Porphyromonas gingivalis.
    Pajukanta R; Asikainen S; Forsblom B; Piekkola M; Jousimies-Somer H
    Oral Microbiol Immunol; 1994 Apr; 9(2):123-5. PubMed ID: 8008429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.